Tempest Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
TPST Nasdaq 2836 www.tempesttx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Tempest Therapeutics, Inc.

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update - Aug 13th, 2026 2:25 pm
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T - Jul 21st, 2026 5:00 am
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026 - Jul 15th, 2026 5:00 am
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors - Jun 4th, 2026 2:37 pm
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds - May 29th, 2026 6:00 am
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update - May 14th, 2026 2:15 pm
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting - May 6th, 2026 5:00 am
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting - Apr 29th, 2026 6:00 am
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T - Apr 22nd, 2026 6:00 am
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts - Apr 14th, 2026 6:00 am
New Strong Buy Stocks for April 10th - Apr 10th, 2026 2:32 am
Tempest Reports Year End 2025 Financial Results and Provides Business Update - Mar 30th, 2026 7:00 am
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026 - Mar 11th, 2026 6:00 am
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026 - Feb 25th, 2026 5:59 am
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets - Feb 11th, 2026 4:59 am
Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets - Feb 4th, 2026 2:47 pm
Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules - Nov 26th, 2025 2:05 pm